Khiron gains high-THC medical cannabis manufacturing quotas from TQG

Khiron Life Sciences Corp., a vertically integrated cannabis company, has recently obtained manufacturing quotas for high-THC medical cannabis from the TQG (Colombian Technical Quotas Group). The manufacturing quotas will authorize Khiron to produce high-THC whole cannabis extract for various domestic purposes as well as for export. 50% of the 9.3 tons approved will be adopted for domestic purposes while the remaining 50% will be used in export activities.

Owing to this authorization of TQG, the company will also be able to produce and market cannabis oils worldwide. The recent attainment comes along the heel of the company’s prior receipt of cultivation quotas, which was in February 2020.

Khiron, which performs core operations in Latin America, is associated with the commercial distribution and production of various medical cannabis products. Export quotas will enhance Khiron’s production of whole plant extract, accessing to medical cannabis market valued at over $1.4 billion, across international regions such as Brazil, Uruguay, and Peru.

Juan Diego Alvarez, Vice President of Regulatory Affairs at Khiron, has reportedly commented that the recent accomplishment of securing the cultivation as well as manufacturing quotas will help cater to the company’s priority of serving various needs of customers in Colombia & other jurisdictions in Latin America. The medical cannabis products that are manufactured by the company will effectively serve a large network of patients suffering from two primary health conditions, i.e. nausea and chronic pain associated with chemotherapy. Mr. Alvarez also added that the medical cannabis business can also be developed through the company’s increased clinical capacity, which includes Institute of Neurology and the Nervous System (ILANS) clinics as well as Zerenia, a fully integrated medical care clinic.

Khiron is projected to hold a production capacity of nearly 1,000,000 high-THC formulation bottles for medicinal purposes, owing to the increased demand for high-THC medical cannabis, domestically and internationally. The company is awaiting the final certification of the GEP laboratory, which is anticipated to be granted in the near future.

Source credit:

https://investors.khiron.ca/investor-information/news-events/press-releases/detail/147/khiron-is-first-company-authorized-to-extract-high-thc